Therapeutic efficacy of danazol in myelodysplastic syndromes

Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome

“…While the studies by Selleri et al [10] and Chabannon et al [20] did not demonstrate a response to danazol, these reports used different criteria and less symptomatic patients. The patients we report on had a poorer prognosis (23 out of 33 patients with IPSS Ն1.5) than in previous published studies [8,9,14]. However, significant responses still were achieved in this population and treatment was associated with few, well-tolerated side effects.…”

“…Early studies with small sample sizes found responders only among patients with lowrisk MDS such as RA or RARS [6,7]. Other studies began danazol in patients with platelet counts up to 110 × 10 9 /L, a group less likely to demonstrate a benefit from a further increase in their platelet counts [8,9]. One study found no responders when response was defined as normalization of platelet counts [10].…”

Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome

“…While the studies by Selleri et al [10] and Chabannon et al [20] did not demonstrate a response to danazol, these reports used different criteria and less symptomatic patients. The patients we report on had a poorer prognosis (23 out of 33 patients with IPSS Ն1.5) than in previous published studies [8,9,14]. However, significant responses still were achieved in this population and treatment was associated with few, well-tolerated side effects.…”

“…Early studies with small sample sizes found responders only among patients with lowrisk MDS such as RA or RARS [6,7]. Other studies began danazol in patients with platelet counts up to 110 × 10 9 /L, a group less likely to demonstrate a benefit from a further increase in their platelet counts [8,9]. One study found no responders when response was defined as normalization of platelet counts [10].…”

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

“…34 Danazol also has been shown to lower the antiplatelet IgG level in patients with ITP who are responding. 35,36 A decrease in the quantity of platelet-associated IgG may not be the only mechanism through which the response to danazol is mediated. 37 Numerous immunological problems, such as the development of autoantibodies and autoimmune diseases, are linked to MDS, 38 and immunosuppressive therapy is effective in certain patients with MDS.…”

“…The DEBBRAH trial had very few of these patients so more data are needed. 36 We know that HER2+ BC has a high brain metastasis incidence; 30% to 50% of patients develop brain metastasis. 37 Brain metastasis is less frequent in HER2-disease, but because most breast cancers are HER2-, in absolute terms, most brain metastasis patients we see clinically have HER2-disease.…”

Pyridoxin‐responsive anaemia in a patient with a history of polycythaemia vera

“…An example of this heterogeneity is seen in the results of the Fe-kinetic studies, in which some of the patients with MDS clearly show ineffective erythropoiesis whereas another group of patients also classified as MDS shows the picture of aplasia. Androgen treatment of MDS is controversial [11][12][13]. Probably androgens may be useful in a subset of patients in stimulating erythropoiesis.…”

Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome

“…While the studies by Selleri et al [10] and Chabannon et al [20] did not demonstrate a response to danazol, these reports used different criteria and less symptomatic patients. The patients we report on had a poorer prognosis (23 out of 33 patients with IPSS Ն1.5) than in previous published studies [8,9,14]. However, significant responses still were achieved in this population and treatment was associated with few, well-tolerated side effects.…”

“…Early studies with small sample sizes found responders only among patients with lowrisk MDS such as RA or RARS [6,7]. Other studies began danazol in patients with platelet counts up to 110 × 10 9 /L, a group less likely to demonstrate a benefit from a further increase in their platelet counts [8,9]. One study found no responders when response was defined as normalization of platelet counts [10].…”

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

“…34 Danazol also has been shown to lower the antiplatelet IgG level in patients with ITP who are responding. 35,36 A decrease in the quantity of platelet-associated IgG may not be the only mechanism through which the response to danazol is mediated. 37 Numerous immunological problems, such as the development of autoantibodies and autoimmune diseases, are linked to MDS, 38 and immunosuppressive therapy is effective in certain patients with MDS.…”

“…The DEBBRAH trial had very few of these patients so more data are needed. 36 We know that HER2+ BC has a high brain metastasis incidence; 30% to 50% of patients develop brain metastasis. 37 Brain metastasis is less frequent in HER2-disease, but because most breast cancers are HER2-, in absolute terms, most brain metastasis patients we see clinically have HER2-disease.…”

Pyridoxin‐responsive anaemia in a patient with a history of polycythaemia vera

“…An example of this heterogeneity is seen in the results of the Fe-kinetic studies, in which some of the patients with MDS clearly show ineffective erythropoiesis whereas another group of patients also classified as MDS shows the picture of aplasia. Androgen treatment of MDS is controversial [11][12][13]. Probably androgens may be useful in a subset of patients in stimulating erythropoiesis.…”

Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome

“…While the studies by Selleri et al [10] and Chabannon et al [20] did not demonstrate a response to danazol, these reports used different criteria and less symptomatic patients. The patients we report on had a poorer prognosis (23 out of 33 patients with IPSS Ն1.5) than in previous published studies [8,9,14]. However, significant responses still were achieved in this population and treatment was associated with few, well-tolerated side effects.…”

“…Early studies with small sample sizes found responders only among patients with lowrisk MDS such as RA or RARS [6,7]. Other studies began danazol in patients with platelet counts up to 110 × 10 9 /L, a group less likely to demonstrate a benefit from a further increase in their platelet counts [8,9]. One study found no responders when response was defined as normalization of platelet counts [10].…”

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

“…34 Danazol also has been shown to lower the antiplatelet IgG level in patients with ITP who are responding. 35,36 A decrease in the quantity of platelet-associated IgG may not be the only mechanism through which the response to danazol is mediated. 37 Numerous immunological problems, such as the development of autoantibodies and autoimmune diseases, are linked to MDS, 38 and immunosuppressive therapy is effective in certain patients with MDS.…”

“…The DEBBRAH trial had very few of these patients so more data are needed. 36 We know that HER2+ BC has a high brain metastasis incidence; 30% to 50% of patients develop brain metastasis. 37 Brain metastasis is less frequent in HER2-disease, but because most breast cancers are HER2-, in absolute terms, most brain metastasis patients we see clinically have HER2-disease.…”

Pyridoxin‐responsive anaemia in a patient with a history of polycythaemia vera

“…An example of this heterogeneity is seen in the results of the Fe-kinetic studies, in which some of the patients with MDS clearly show ineffective erythropoiesis whereas another group of patients also classified as MDS shows the picture of aplasia. Androgen treatment of MDS is controversial [11][12][13]. Probably androgens may be useful in a subset of patients in stimulating erythropoiesis.…”